Tetragenex Investors Main Page

Home About Tetragenex Product Technology Our Team Scientific Publications Investors Company News Careers Contact Us

Since 1994, we have raised over $70 million through the private equity markets. We believe that we are well capitalized to execute our business plan to license and develop pharmaceuticals for the treatment of major depression and other CNS diseases.

Tetragenex Pharmaceuticals Inc. is funded and supported by private investors, including a distinguished and experienced group of institutional and biotechnology investors. In addition, our senior management team has invested approximately $9 million of personal funds in the Company, demonstrating their strong belief in the effectiveness of our technology.

Major institutional investors include:

Sachsen LB Corporate Finance Holding GmbH (the corporate venture arm of Sachsen Lundesbank of Germany)

KBC Bank of Belgium and its affiliates (including funds under management by KBC)

Quintiles Transnational Corp.

Volvo Results Foundation

Astaire & Partners Limited, a London based Securities Firm

European Development Capital Corporation

Stichting Ruischend Loof

For more information, please Contact Us.

All outstanding shares of the company were re-issued, after we emerged from bankruptcy as Tetragenex Pharmaceuticals, Inc, by our transfer agent, Transfer Online. If you did not receive the welcome letter from Transfer Online, detailing how you can view your holdings online and how you can receive your certificates, please contact Jack Hamlin at Tetragenex for that information.